Artax Biopharma is a clinical-stage biotechnology company transforming the treatment of T Cell-driven autoimmune diseases. Our first-in-class oral small molecules aim to deliver immune system modulation without immunosuppression, potentially unlocking new treatment options. Our lead program AX-158 will deliver Phase 2a Proof of Concept study in psoriasis later in 2024. In contrast to agents targeting individual cytokines, we believe our approach will allow us to address a broad spectrum of patients. By having the potential to impact multiple cytokines, we hope to address areas of high unmet need beyond where targeted therapies have achieved success. We believe there is significant potential for our approach to revolutionize treatment of T Cell-driven diseases. Immunomodulation maintains healthy control of the immune system and addresses the underlying source of T Cell-driven diseases. Central to a well-functioning immune system is the T Cell Receptor (TCR). When TCR signaling becomes dysregulated, it causes T Cell-driven conditions, including autoimmune diseases, and induced T Cell pathologies where medical treatments result in immune reactions (such as stem cell transplants resulting in acute graft-versus-host-disease or immuno-oncology treatments resulting in immune related-adverse events). We believe the immunomodulation mechanism offered by our investigational agents holds broad potential to revolutionize how these T Cell-driven autoimmune diseases are addressed, while not impairing the ability of a patient’s immune system to function properly. Artax Biopharma is based in the Boston area and raised Series A & B from Advent Life Sciences, Sound Bioventures, and Columbus Venture Partners. For more info, see artaxbiopharma.com